DERBY, U.K. - January 29, 2019-
STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today
that it will host a conference call to discuss its fiscal 2019
third quarter financial results at 10:00 a.m. Eastern Time on
Tuesday, February 12, 2019. The conference call can be heard
live over the Internet at www.steris-ir.com or via phone by dialing
1-833-535-2199 in the United States or 1-412-902-6776
internationally, then asking to join the conference call for STERIS
plc.
For those unable to listen to the conference call
live, a replay will be available beginning at 12:00 p.m. Eastern
Time on February 12, 2019, either over the Internet at
www.steris-ir.com or via phone. To access the replay of the
call, please use the access code 10127887 and dial 1-877-344-7529
in the United States or 1-412-317-0088 internationally.
About STERIS
STERIS's mission is to help our Customers create a
healthier and safer world by providing innovative healthcare and
life science product and service solutions around the globe. For
more information, visit www.steris.com.
Investor Contact:
Julie Winter, Senior Director, Investor Relations
and Corporate Communications
Julie_Winter@steris.com
+1.440.392.7245
Media Contact:
Stephen Norton, Senior Director, Corporate
Communications
Stephen_Norton@steris.com
+1.440.392.7482
Forward-Looking
Statements
This release and the referenced conference call
may contain statements concerning certain trends, expectations,
forecasts, estimates, or other forward-looking information
affecting or relating to STERIS or its industry, products or
activities that are intended to qualify for the protections
afforded "forward-looking statements" under the Private Securities
Litigation Reform Act of 1995 and other laws and regulations.
Forward-looking statements speak only as to the date the statement
is made and may be identified by the use of forward-looking terms
such as "may," "will," "expects," "believes," "anticipates,"
"plans," "estimates," "projects," "targets," "forecasts,"
"outlook," "impact," "potential," "confidence," "improve,"
"optimistic," "deliver," "orders," "backlog," "comfortable,"
"trend", and "seeks," or the negative of such terms or other
variations on such terms or comparable terminology. Many important
factors could cause actual results to differ materially from those
in the forward-looking statements including, without limitation,
disruption of production or supplies, changes in market conditions,
political events, pending or future claims or litigation,
competitive factors, technology advances, actions of regulatory
agencies, and changes in laws, government regulations, labeling or
product approvals or the application or interpretation thereof.
Other risk factors are described in STERIS's securities filings,
including Item 1A of STERIS's Annual Report on Form 10-K for
the year ended March 31, 2018. Many of these important factors
are outside of STERIS's control. No assurances can be provided as
to any result or the timing of any outcome regarding matters
described in STERIS's securities filings or otherwise with respect
to any regulatory action, administrative proceedings, government
investigations, litigation, warning letters, cost reductions,
business strategies, earnings or revenue trends or future financial
results. References to products are summaries only and should not
be considered the specific terms of the product clearance or
literature. Unless legally required, STERIS does not undertake to
update or revise any forward-looking statements even if events make
clear that any projected results, express or implied, will not be
realized. Other potential risks and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation,
(a) the receipt of approval of STERIS's shareholders of the
redomiciliation transaction, (b) any regulatory or court approvals
required for the redomiciliation transaction not being obtained on
the terms expected or on the anticipated schedule, (c) the parties'
ability to meet expectations regarding the timing, completion and
accounting and tax treatments of the redomiciliation transaction,
(d) operating costs, Customer loss and business disruption
(including, without limitation, difficulties in maintaining
relationships with employees, Customers, clients or suppliers)
being greater than expected following the redomiciliation
transaction, (e) STERIS's ability to meet expectations regarding
the accounting and tax treatment of the Tax Cuts and Jobs Act
("TCJA") or the possibility that anticipated benefits resulting
from the TCJA will be less than estimated, (f) changes in tax
laws or interpretations that could increase our consolidated tax
liabilities, including, if the redomiciliation transaction is
consummated, changes in tax laws that would result in STERIS
Ireland being treated as a domestic corporation for United States
federal tax purposes, (g) the potential for increased pressure
on pricing or costs that leads to erosion of profit margins,
(h) the possibility that market demand will not develop for
new technologies, products or applications or services, or business
initiatives will take longer, cost more or produce lower benefits
than anticipated, (i) the possibility that application of or
compliance with laws, court rulings, certifications, regulations,
regulatory actions, including without limitation those relating to
FDA warning notices or letters, government investigations, the
outcome of any pending FDA requests, inspections or submissions, or
other requirements or standards may delay, limit or prevent new
product introductions, affect the production and marketing of
existing products or services or otherwise affect STERIS's
performance, results, prospects or value, (j) the potential of
international unrest, economic downturn or effects of currencies,
tax assessments, tariffs and/or other trade barriers, adjustments
or anticipated rates, raw material costs or availability, benefit
or retirement plan costs, or other regulatory compliance costs,
(k) the possibility of reduced demand, or reductions in the
rate of growth in demand, for STERIS's products and services,
(l) the possibility of delays in receipt of orders, order
cancellations, or delays in the manufacture or shipment of ordered
products or in the provision of services, (m) the possibility
that anticipated growth, cost savings, new product acceptance,
performance or approvals, or other results may not be achieved, or
that transition, labor, competition, timing, execution, regulatory,
governmental, or other issues or risks associated with STERIS's
businesses, industry or initiatives including, without limitation,
those matters described in STERIS's 10-K for the year ended
March 31, 2018 and other securities filings, may adversely
impact STERIS's performance, results, prospects or value,
(n) the impact on STERIS and its operations, or tax
liabilities, of Brexit or the exit of other member countries from
the EU, and the Company's ability to respond to such impacts,
(o) the impact on STERIS and its operations of any
legislation, regulations or orders, including but not limited to
any new trade or tax legislation, regulations or orders, that may
be implemented by the U.S. administration or Congress, or of any
responses thereto, (p) the possibility that anticipated
financial results or benefits of recent acquisitions, or of
STERIS's restructuring efforts, or of recent divestitures, or of
the targeted restructuring plan will not be realized or will be
other than anticipated, and (q) the effects of contractions in
credit availability, as well as the ability of STERIS's Customers
and suppliers to adequately access the credit markets when
needed.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Steris Corporation via Globenewswire
STERIS (NYSE:STE)
Historical Stock Chart
From Mar 2024 to Apr 2024
STERIS (NYSE:STE)
Historical Stock Chart
From Apr 2023 to Apr 2024